Overview

Pregabalin Peripheral Neuropathic Pain Study

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of pregabalin, using a flexible, optimized dose schedule with dose adjustment based on Daily Pain Rating Scale (DPRS), compared to placebo in subjects with peripheral neuropathic pain.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Pregabalin